Nasdaq

Rhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of Obesity

-- Uncovering Rare Obesity program may help determine underlying cause of severe obesity ---- Program increases access to genetic testing to improve diagnosis of rare genetic disorders of obesity -- ...

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...
Nasdaq

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing ...

-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results ...
Hosted on MSN

Rhythm secures Australian lab partner to scale Genetype testing

Rhythm partners with Australian Genome Research Facility to establish Australian commercial-scale processing for geneType The partnership will process more than 100,000 tests per year to support local ...
The Australian

Rhythm wins NATA accreditation for ColoSTAT colorectal cancer blood test, paving way for Australian launch

Test now included in the accredited scope of Rhythm’s Parkville laboratory, enabling it to be offered as an accredited clinical test to clinicians and patients across Australia The National ...